Adamas to Announce Fourth Quarter 2019 Financial Results and Host Conference Call on February 25, 2020
February 19 2020 - 4:02PM
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that
the company will report 2019 fourth quarter financial results on
Tuesday, February 25, 2020, after market close. Subsequently,
Adamas’ management team will host a conference call and webcast at
4:30 p.m. Eastern Time to discuss the financial results and provide
a corporate update.
Investor Conference Call and
Webcast The conference call can be accessed by dialing
(844) 215-3280 for participants in the U.S. or Canada and
(484) 747-6383 for international callers. The webcast can be
accessed live via the investor section of the Adamas website at
ir.adamaspharma.com/events-presentations and will be available for
replay until May 25, 2020.
About Adamas Pharmaceuticals,
Inc.At Adamas, our purpose and vision are clear:
deliver innovative medicines that make a clinically meaningful
difference for patients, caregivers and society. We are a
fully-integrated company focused on growing a portfolio of
therapies to address a range of neurological diseases. In
2018, Adamas successfully launched GOCOVRI® (amantadine)
extended-release capsules, the first and only FDA-approved
medicine for the treatment of dyskinesia in patients with
Parkinson’s disease receiving levodopa-based therapy, with or
without concomitant dopaminergic medications. GOCOVRI is also the
only medicine clinically proven to reduce both dyskinesia and OFF.
For more information, please visit www.adamaspharma.com.
Contact
Investors: Peter VozzoManaging Director, Westwicke443-213-0505
peter.vozzo@westwicke.com
Media: Sarah MathiesonVice President, Corporate
Communications510-450-3528smathieson@adamaspharma.com
Adamas Pharmaceuticals (NASDAQ:ADMS)
Historical Stock Chart
From May 2024 to Jun 2024
Adamas Pharmaceuticals (NASDAQ:ADMS)
Historical Stock Chart
From Jun 2023 to Jun 2024